Circulating tumor DNA as a predictive biomarker for treatment response and survival in metastatic colorectal cancer.

IF 2.5 3区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY International Journal of Colorectal Disease Pub Date : 2024-12-17 DOI:10.1007/s00384-024-04785-7

Mengying Kou, Ying Deng

{"title":"Circulating tumor DNA as a predictive biomarker for treatment response and survival in metastatic colorectal cancer.","authors":"Mengying Kou, Ying Deng","doi":"10.1007/s00384-024-04785-7","DOIUrl":null,"url":null,"abstract":"Purpose: To explore the potential of circulating tumor DNA (ctDNA) as a prognostic biomarker to predict treatment response and survival outcomes in patients with metastatic colorectal cancer (mCRC).Methods: A retrospective analysis was conducted on 134 patients with mCRC who were treated between January 2020 and December 2021. The patients were classified into ctDNA-negative and ctDNA-positive groups based on plasma ctDNA detection. Demographic, clinical, and laboratory parameters, treatment response, survival outcomes, and adverse events were recorded and analyzed.Results: No significant differences were observed in baseline characteristics between the two groups. Compared to the ctDNA-positive patients, ctDNA-negative patients exhibited superior outcomes, including a higher objective response rate (65.22% vs. 46.15%), disease control rate (81.16% vs. 63.08%), progression-free survival (8.24 ± 1.02 vs. 7.86 ± 0.91 months), overall survival (24.58 ± 3.58 vs. 23.27 ± 3.46 months), and 1-year survival rate (73.91% vs. 55.38%). The ctDNA-positive group had a significantly higher incidence of adverse events. Correlation analyses revealed significant associations between ctDNA status, tumor markers, treatment response, and survival outcomes.Conclusions: ctDNA is a promising noninvasive biomarker for predicting treatment response, survival, and adverse events in mCRC, potentially guiding personalized therapeutic strategies.","PeriodicalId":13789,"journal":{"name":"International Journal of Colorectal Disease","volume":"39 1","pages":"203"},"PeriodicalIF":2.5000,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11649706/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Colorectal Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00384-024-04785-7","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To explore the potential of circulating tumor DNA (ctDNA) as a prognostic biomarker to predict treatment response and survival outcomes in patients with metastatic colorectal cancer (mCRC).

Methods: A retrospective analysis was conducted on 134 patients with mCRC who were treated between January 2020 and December 2021. The patients were classified into ctDNA-negative and ctDNA-positive groups based on plasma ctDNA detection. Demographic, clinical, and laboratory parameters, treatment response, survival outcomes, and adverse events were recorded and analyzed.

Results: No significant differences were observed in baseline characteristics between the two groups. Compared to the ctDNA-positive patients, ctDNA-negative patients exhibited superior outcomes, including a higher objective response rate (65.22% vs. 46.15%), disease control rate (81.16% vs. 63.08%), progression-free survival (8.24 ± 1.02 vs. 7.86 ± 0.91 months), overall survival (24.58 ± 3.58 vs. 23.27 ± 3.46 months), and 1-year survival rate (73.91% vs. 55.38%). The ctDNA-positive group had a significantly higher incidence of adverse events. Correlation analyses revealed significant associations between ctDNA status, tumor markers, treatment response, and survival outcomes.

Conclusions: ctDNA is a promising noninvasive biomarker for predicting treatment response, survival, and adverse events in mCRC, potentially guiding personalized therapeutic strategies.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

目的：探讨循环肿瘤DNA（ctDNA）作为预后生物标志物的潜力，以预测转移性结直肠癌（mCRC）患者的治疗反应和生存结果：对2020年1月至2021年12月期间接受治疗的134名mCRC患者进行了回顾性分析。根据血浆ctDNA检测结果将患者分为ctDNA阴性组和ctDNA阳性组。记录并分析了人口统计学、临床和实验室参数、治疗反应、生存结果和不良事件：结果：两组患者的基线特征无明显差异。与ctDNA阳性患者相比，ctDNA阴性患者的疗效更好，包括客观反应率（65.22% vs. 46.15%）、疾病控制率（81.16% vs. 63.08%）、无进展生存期（8.24 ± 1.02 vs. 7.86 ± 0.91个月）、总生存期（24.58 ± 3.58 vs. 23.27 ± 3.46个月）和1年生存率（73.91% vs. 55.38%）。ctDNA阳性组的不良事件发生率明显更高。相关性分析显示，ctDNA状态、肿瘤标志物、治疗反应和生存结果之间存在显著关联。结论：ctDNA是一种很有前景的非侵入性生物标记物，可用于预测mCRC的治疗反应、生存和不良事件，从而为个性化治疗策略提供潜在指导。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

International Journal of Colorectal Disease 医学-外科

CiteScore

4.90

自引率

3.60%

发文量

206

审稿时长

3-8 weeks

期刊介绍： The International Journal of Colorectal Disease, Clinical and Molecular Gastroenterology and Surgery aims to publish novel and state-of-the-art papers which deal with the physiology and pathophysiology of diseases involving the entire gastrointestinal tract. In addition to original research articles, the following categories will be included: reviews (usually commissioned but may also be submitted), case reports, letters to the editor, and protocols on clinical studies. The journal offers its readers an interdisciplinary forum for clinical science and molecular research related to gastrointestinal disease.